High-efficacy anti-CD20 therapy is now the baseline in multiple sclerosis, so the next competitive line is not relapse control but treatment preference: route of administration, monitoring burden, and which care setting can actually deliver it. Roche, Novartis and Sanofi are each building a different answer to that question, and the therapy that wins an account may be decided by fit rather than mechanism alone.
Why has anti-CD20 therapy changed what MS competition is about?
Anti-CD20 therapies have become central to high-efficacy multiple sclerosis treatment, but they no longer compete on efficacy alone, and they are not all built around the same care model. Roche's Ocrevus helped establish B-cell depletion as a standard across relapsing forms of MS and primary progressive MS, delivered by infusion in a hospital or specialist setting that brings its own capacity, staffing and monitoring requirements.
Novartis's Kesimpta offers a different proposition entirely: a self-administered subcutaneous anti-CD20 therapy that gives clinicians and patients an option that can reduce dependence on infusion-centre capacity while keeping the same high-efficacy framing. TG Therapeutics' Briumvi adds a third anti-CD20 option, with an infusion profile that affects site throughput and account-level positioning in its own way.
The result is that once a therapy clears the efficacy bar anti-CD20 treatment set, the next question a neurologist or a treatment network asks is rarely about mechanism. It is about which care model, infusion, self-administration or eventually an oral option, actually fits how that account wants to deliver ongoing care.
- 01
Map the delivery model
Confirm whether the account runs on infusion capacity, self-administration or both.
- 02
Match the account
Position the therapy against the specific care model each account can actually support.
- 03
Build switching evidence
Show what comes before and after the therapy in a realistic treatment sequence.
- 04
Plan for progression
Evidence a role beyond relapse control as progression-focused data reshapes expectations.
How are Roche and Novartis building different treatment-preference propositions?
Roche's position has historically been tied to Ocrevus and its broad relapsing and progressive MS franchise, built on the infusion-based care model. Fenebrutinib, an investigational oral BTK inhibitor, could give the company a route into a different treatment format and a progression-focused clinical conversation. In February 2026, Roche stated that fenebrutinib was the first investigational medicine in more than a decade to reduce disability progression in primary progressive MS.
For Roche, the opportunity is not simply to add a new asset to the portfolio. It is to give neurologists a choice across infusion-based B-cell depletion and an oral, progression-focused therapy, so the same account can be served by more than one care model depending on where a patient sits in their disease course.
Novartis already occupies a contrasting position with Kesimpta's self-administered model, competing on convenience and reduced infusion-centre reliance rather than on a different mechanism. If the company adds an oral BTK option to that portfolio, it could address several points in the treatment journey at once, from early high-efficacy treatment through to patients for whom oral administration or progression-related evidence becomes the deciding factor. The lesson generalising across both companies is that a product portfolio increasingly competes as a choice architecture, the same shift reshaping how obesity drug makers are building for a funded-patient funnel rather than for a single molecule.
Why is disease progression becoming the new battleground?
For years, relapse reduction was the central clinical and commercial metric in MS. Disease progression, particularly progression independent of relapse activity, has remained harder to treat, which is why BTK inhibitors are drawing so much attention: the mechanism offers a plausible route to influencing both peripheral and central nervous system immune activity, creating a rationale for use in progressive disease as well as relapsing disease.
Sanofi's Cenrifki, known generically as tolebrutinib, illustrates how significant this shift is. In June 2026, the European Commission approved Cenrifki for non-relapsing secondary progressive MS, positioning it as the first disability-targeting therapy for that population. For Sanofi, the opportunity is not to compete in the broad relapsing-MS market at all, but to create relevance in a segment defined by disability progression rather than relapse frequency.
The open question is whether progression-focused evidence resets what neurologists expect from every new MS therapy going forward. If it does, established high-efficacy brands will need to show a credible role in preventing disability accumulation, not just relapse control, to hold their position.
| United States | European Union | |
|---|---|---|
| Key adoption setting | MS centres, community neurology, infusion and specialty-pharmacy networks | Hospital specialists and country-specific national pathways |
| Commercial friction | Site of care, payer controls, infusion capacity, channel coordination | Hospital protocols, specialist capacity, national guidelines |
| Primary challenge | Win account-level preference and support initiation | Earn a place in country-specific treatment pathways |
Who actually decides which therapy gets used?
Treatment preference is not decided in the abstract. It is shaped by the institutions and professionals actually responsible for delivering care. An infusion-based therapy may be clinically well understood but operationally demanding for a given site. A self-administered therapy may improve convenience but requires a different adherence and support infrastructure. An oral medicine may cut administration burden but brings its own monitoring and safety profile.
That means commercial success increasingly depends on understanding where a given therapy fits at the account level, whether that account is an academic MS centre leading adoption of complex new therapies, a community neurology practice deciding how far high-efficacy treatment can scale beyond specialist care, an infusion centre weighing scheduling and throughput, or a specialty pharmacy coordinating a self-administered or oral regimen.
A company that treats every account the same, regardless of its infusion capacity, staffing model or patient population, is treating a care-model decision as if it were a clinical one. The two are related, but they are not the same question, and account-level research increasingly has to answer both.
Why can the same therapy face different adoption models in the US and EU?
The US and EU share much of the same MS science, but the route to treatment preference differs. In the US, MS centres, community neurology practices, infusion networks, specialty pharmacies and payer policies all shape treatment selection, so a company has to address specialist confidence alongside account workflow, site-of-care economics and pharmacy coordination all at once.
In the EU, hospital-based care, national treatment guidelines, country-specific reimbursement decisions and specialist-centre capacity play a larger role. A product's clinical profile can look identical across both markets while its path to routine use looks nothing alike.
Sanofi's EU approval of Cenrifki shows how regulatory progress can open a distinct regional opportunity in progressive disease well ahead of any equivalent US decision. Roche's fenebrutinib data could shape a similar, separate conversation if it translates into regulatory and clinical adoption on its own timeline. The underlying science is shared. The treatment-preference model that decides adoption is local.